AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9495426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 2 mg
Number of subjects: 314
Study 9495426 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 314
Study 9495426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 7946944 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily)
Number of subjects: 0
Study 7946944 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hydroxypropranolol (4OHP)
Number of subjects: 0
Study 7946944 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 3186373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft palate group (35 subjects)
Number of subjects: 35
Study 3186373 — intervention group
Group type: COMPARATOR
Intervention: Control group (68 subjects without cleft palates)
Number of subjects: 35
Study 30883291 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 30883291 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0
Study 30883291 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 0
Study 30883291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30067581 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based parent-adolescent sexual communication program
Number of subjects: 492
Study 30067581 — intervention group
Group type: COMPARATOR
Intervention: Web-based physical activity program
Number of subjects: 492
Study 26242993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track intervention
Number of subjects: 891
Study 26242993 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control
Number of subjects: 891
Study 25062651 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based insulin glargine dose titration regimen
Number of subjects: 149
Study 25062651 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose level-based insulin glargine dose titration regimen
Number of subjects: 149
Study 25062651 — intervention group
Group type: COMPARATOR
Intervention: Current dose-based insulin glargine dose titration regimen
Number of subjects: 149
Study 21980058 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 μg)
Number of subjects: 14
Study 21980058 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone propionate (50/250 μg)
Number of subjects: 14
Study 21980058 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (250 μg)
Number of subjects: 14
Study 21980058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19130643 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (4 x 5 gxd-1) during days 15-21
Number of subjects: 7
Study 19130643 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin; 4 x 5 gxd-1) during days 1-7
Number of subjects: 7
Study 17877164 — intervention group
Group type: EXPERIMENTAL
Intervention: A + C vaccine
Number of subjects: 34543
Study 17877164 — intervention group
Group type: COMPARATOR
Intervention: Vi polysaccharide vaccine
Number of subjects: 34543
Study 15165407 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic practices (selected asanas for 45 minutes, pranayama for 15 minutes in the morning; preparatory postures for 15 minutes, pranayama for 15 minutes, meditation for 30 minutes in the evening) for 3 months
Number of subjects: 30
Study 15165407 — intervention group
Group type: COMPARATOR
Intervention: Body flexibility exercises for 40 minutes, slow running for 20 minutes in the morning; games for 60 minutes in the evening for 3 months
Number of subjects: 30
Study 14664747 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitexina
Number of subjects: 70
Study 14664747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9689804 — intervention group
Group type: EXPERIMENTAL
Intervention: Amosite exposure
Number of subjects: 83
Study 9689804 — intervention group
Group type: EXPERIMENTAL
Intervention: Chrysotile exposure
Number of subjects: 83
Study 9689804 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocidolite exposure
Number of subjects: 83
Study 9689804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed fibre exposures
Number of subjects: 83
Study 9689804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremolite exposure
Number of subjects: 83
Study 8082522 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra therapeutic shoe coverage
Number of subjects: 3428
Study 8082522 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard Medicare coverage)
Number of subjects: 3428
Study 2645508 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrazepam
Number of subjects: 47
Study 2645508 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 47
Study 2645508 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 47
Study 2645508 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Tetrazepam, Baclofen, Tizanidine)
Number of subjects: 47
Study 30352770 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical therapy with a foot-worn biomechanical device
Number of subjects: 50
Study 29071986 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy combined with nutrition consultation
Number of subjects: 71
Study 29071986 — intervention group
Group type: COMPARATOR
Intervention: Nutrition consultation (control group)
Number of subjects: 71
Study 29071986 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 71
Study 25892145 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/day)
Number of subjects: 483
Study 25892145 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (40 mg/m2 per week)
Number of subjects: 483
Study 24165884 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg bid for 14 days with cocktail on days 1 and 14
Number of subjects: 0
Study 24165884 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg bid for 12 days with digoxin on day 8
Number of subjects: 0
Study 22852050 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-only (CHO; 75 g per beverage)
Number of subjects: 12
Study 22852050 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate/low-protein (HCLP; 45 g CHO, 25 g Pro, 0.5 g fat)
Number of subjects: 12
Study 22852050 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate/high-protein (LCHP; 8 g CHO, 55 g Pro, 4 g fat)
Number of subjects: 12
Study 22852050 — intervention group
Group type: EXPERIMENTAL
Intervention: EX2 performance with CHO
Number of subjects: 12
Study 22852050 — intervention group
Group type: EXPERIMENTAL
Intervention: EX2 performance with HCLP
Number of subjects: 12
Study 22852050 — intervention group
Group type: EXPERIMENTAL
Intervention: EX2 performance with LCHP
Number of subjects: 12
Study 22852050 — intervention group
Group type: COMPARATOR
Intervention: All treatments (CHO, HCLP, LCHP)
Number of subjects: 12
Study 19339121 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSUS scale
Number of subjects: 230
Study 17519069 — intervention group
Group type: EXPERIMENTAL
Intervention: LOP/SIM 2 mg/125 mg
Number of subjects: 483
Study 17519069 — intervention group
Group type: COMPARATOR
Intervention: LOP 2 mg
Number of subjects: 483
Study 17519069 — intervention group
Group type: COMPARATOR
Intervention: SIM 125 mg
Number of subjects: 483
Study 17519069 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 483
Study 14688160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg 3 h prior to SE)
Number of subjects: 100
Study 14688160 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (400 microg 3 h prior to SE)
Number of subjects: 100
Study 11768727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 32
Study 11768727 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 32
Study 9260007 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (10 mg PCA bolus)
Number of subjects: 34
Study 9260007 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol + Droperidol (10 mg tramadol + 0.1 mg droperidol PCA bolus)
Number of subjects: 34
Study 8500303 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Field Quality Control Procedures
Number of subjects: 14000
Study 8500303 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Test Protocols
Number of subjects: 14000
Study 8500303 — intervention group
Group type: EXPERIMENTAL
Intervention: Technician Training and Certification Procedures
Number of subjects: 14000
Study 8500303 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Control Assessment Techniques
Number of subjects: 14000
Study 3440104 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 5 g orally at hourly intervals for 7 h
Number of subjects: 8
Study 3440104 — intervention group
Group type: COMPARATOR
Intervention: Equal volume of water
Number of subjects: 8
Study 31524008 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulsed Nd:YAG laser (1,064 nm)
Number of subjects: 22
Study 31524008 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 22
Study 29301544 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) training
Number of subjects: 120
Study 29301544 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 120
Study 27502225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag immersion method using 60mL of 2% chlorhexidine with 70% alcohol
Number of subjects: 51
Study 27502225 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze painting using 2% chlorhexidine with 70% alcohol
Number of subjects: 51
Study 25605828 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic drainage system
Number of subjects: 105
Study 25605828 — intervention group
Group type: COMPARATOR
Intervention: Traditional water seal drainage
Number of subjects: 105
Study 25605828 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of pleural adhesions or incomplete fissure
Number of subjects: 105
Study 23354809 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam dosing strategy of 44.44/5.56 mg/kg/dose every 8 or 12 hours
Number of subjects: 71
Study 23354809 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic models for piperacillin
Number of subjects: 71
Study 23354809 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic models for tazobactam
Number of subjects: 71
Study 23354809 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic models for piperacillin and tazobactam
Number of subjects: 71
Study 20872199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole
Number of subjects: 91
Study 20872199 — intervention group
Group type: EXPERIMENTAL
Intervention: Flomoxef
Number of subjects: 91
Study 20872199 — intervention group
Group type: COMPARATOR
Intervention: Cefmetazole vs Flomoxef
Number of subjects: 91
Study 18353242 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIG injection every four weeks until labor (experimental group with HBsAg positive)
Number of subjects: 279
Study 18353242 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIG injection every four weeks until labor (experimental group with both HBsAg and HBeAg positive)
Number of subjects: 279
Study 18353242 — intervention group
Group type: COMPARATOR
Intervention: No HBIG (control group with HBsAg positive)
Number of subjects: 279
Study 18353242 — intervention group
Group type: COMPARATOR
Intervention: No HBIG (control group with both HBsAg and HBeAg positive)
Number of subjects: 279
Study 16600745 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 73
Study 16600745 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 73
Study 12890165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) 120 mg/day for 14 days
Number of subjects: 32
Study 12890165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) 240 mg/day for 14 days
Number of subjects: 32
Study 12890165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) 480 mg/day for 14 days
Number of subjects: 32
Study 12890165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 10976194 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I)
Number of subjects: 121
Study 10976194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II)
Number of subjects: 121
Study 9315415 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant implants
Number of subjects: 0
Study 9315415 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroid copper intrauterine device (IUD)
Number of subjects: 0
Study 8375240 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine +/‐ mexiletine for deep pain, capsaicin for superficial pain, stretching exercises and metaxalone +/‐ piroxican for muscular pain
Number of subjects: 75
Study 8375240 — intervention group
Group type: COMPARATOR
Intervention: untreated patients
Number of subjects: 75
Study 2878490 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy with two injections a day (CTh)
Number of subjects: 39
Study 2878490 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump (CSII)
Number of subjects: 39
Study 2878490 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple injections (MI)
Number of subjects: 39
Study 30036854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg/day
Number of subjects: 141
Study 30036854 — intervention group
Group type: COMPARATOR
Intervention: Injectable disease-modifying therapies (iDMTs)
Number of subjects: 141
Study 30036854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 141
Study 30036854 — intervention group
Group type: COMPARATOR
Intervention: iDMTs
Number of subjects: 141
Study 30036854 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod and iDMTs
Number of subjects: 141
Study 27456085 — intervention group
Group type: EXPERIMENTAL
Intervention: BADI (Brief Adjustment Disorder Intervention) - internet-based modular program with four modules: Relaxation, Time management, Mindfulness, Strengthening relationships.
Number of subjects: 0
Study 27456085 — intervention group
Group type: COMPARATOR
Intervention: Control group - participants wait one month before gaining access to the BADI intervention.
Number of subjects: 0
Study 26685634 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary vacuum‐formed retainer combined with a mandibular canine‐to‐canine retainer
Number of subjects: 0
Study 26685634 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary vacuum‐formed retainer combined with stripping of the mandibular anterior teeth
Number of subjects: 0
Study 26685634 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated positioner
Number of subjects: 0
Study 26685634 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum‐formed retainer (VFR) combined with a canine‐to‐canine retainer (CTC)
Number of subjects: 0
Study 26685634 — intervention group
Group type: EXPERIMENTAL
Intervention: All three retention methods
Number of subjects: 0
Study 26685634 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance levels (excellent or good)
Number of subjects: 0
Study 26685634 — intervention group
Group type: EXPERIMENTAL
Intervention: Body height, initial crowding, gender
Number of subjects: 0
Study 22297398 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intravenous zoledronic acid (ZOL)
Number of subjects: 82
Study 22297398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 20350675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 15
Study 20350675 — intervention group
Group type: COMPARATOR
Intervention: Detuned ultrasound
Number of subjects: 15
Study 18331237 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton MRS (1H MRS) for hepatic fat measurement
Number of subjects: 244
Study 18331237 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus MRS (31P MRS) for ATP measurement
Number of subjects: 244
Study 15976341 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate testing for C reactive protein (CRP) and white blood cell count (WBC) before initial consultation (group 1)
Number of subjects: 301
Study 15976341 — intervention group
Group type: COMPARATOR
Intervention: No advance testing (group 2)
Number of subjects: 301
Study 15976341 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate testing for CRP and WBC (group 1)
Number of subjects: 301
Study 15976341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 301
Study 11481623 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 6 MU daily of interferon alfa 2b plus 800 mg of ribavirin
Number of subjects: 44
Study 11481623 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with 6 MU daily of IFN‐alpha2b
Number of subjects: 44
Study 11481623 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with twice‐daily intravenous administration with 3MU of IFN‐beta
Number of subjects: 44
Study 11481623 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with daily intravenous administration with 6 MU of IFN‐beta
Number of subjects: 44
Study 9744582 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial flexion true sagittal (FS) MR images
Number of subjects: 23
Study 9744582 — intervention group
Group type: COMPARATOR
Intervention: Extension sagittal oblique (ESO) MR images
Number of subjects: 23
Study 8001404 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide with oxygen inhalation
Number of subjects: 34
Study 8001404 — intervention group
Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 34
Study 2567873 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting (Birth Cushion)
Number of subjects: 427
Study 2567873 — intervention group
Group type: COMPARATOR
Intervention: Conventional semirecumbent management
Number of subjects: 427
Study 8132369 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily antibiotic prophylaxis with Phenoxymethylpenicillin (or erythromycin for penicillin-allergic patients)
Number of subjects: 40
Study 8132369 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 40
Study 385948 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA alone
Number of subjects: 60
Study 385948 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA with BCG-cell wall skeleton as an adjuvant
Number of subjects: 60
Study 385948 — intervention group
Group type: COMPARATOR
Intervention: BCG-cell wall skeleton only
Number of subjects: 60
Study 385948 — intervention group
Group type: COMPARATOR
Intervention: No immunotherapy
Number of subjects: 60
Study 30503748 — intervention group
Group type: EXPERIMENTAL
Intervention: NTCELL® (intra-striatal delivery)
Number of subjects: 18
Study 30503748 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery (control)
Number of subjects: 18
Study 28329080 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with GCS<15 (altered mental status)
Number of subjects: 326
Study 28329080 — intervention group
Group type: COMPARATOR
Intervention: Patients with GCS=15 (normal mental status)
Number of subjects: 326
Study 25851632 — intervention group
Group type: EXPERIMENTAL
Intervention: EVE/BEV (everolimus 10 mg/day + bevacizumab 10 mg/kg every 2 weeks)
Number of subjects: 365
Study 25851632 — intervention group
Group type: COMPARATOR
Intervention: IFN/BEV (interferon 9 MIU 3 times/week + bevacizumab 10 mg/kg every 2 weeks)
Number of subjects: 365
Study 25851632 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EVE/BEV and IFN/BEV
Number of subjects: 365
Study 23646475 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing Injection (XI), intravenously injected with 100 mL QI in 100 mL normal saline, twice daily for seven days
Number of subjects: 76
Study 23646475 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 76
Study 21494043 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time group with real-time viewer and polyethylene glycol (500 ml) or metoclopramide (10 mg) if capsule in stomach.
Number of subjects: 80
Study 21494043 — intervention group
Group type: COMPARATOR
Intervention: Conventional group without preparation.
Number of subjects: 80
Study 21494043 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time group with real-time viewer.
Number of subjects: 80
Study 19138700 — intervention group
Group type: EXPERIMENTAL
Intervention: Rod reaction times plotted against the spatial luminance ratio (L(max)/L(min)) between the stimulus and its background.
Number of subjects: 0
Study 19138700 — intervention group
Group type: EXPERIMENTAL
Intervention: S-cone selective increments and decrements reaction times.
Number of subjects: 0
Study 17966177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% foam (n=427)
Number of subjects: 1162
Study 17966177 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam (n=420)
Number of subjects: 1162
Study 17966177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole cream (n=210)
Number of subjects: 1162
Study 17966177 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (n=105)
Number of subjects: 1162
Study 15376308 — intervention group
Group type: EXPERIMENTAL
Intervention: Living donor liver transplantation (LDLT)
Number of subjects: 76
Study 15376308 — intervention group
Group type: COMPARATOR
Intervention: Deceased donor liver transplantation (DDLT)
Number of subjects: 76
Study 15376308 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (LDLT and DDLT)
Number of subjects: 76
Study 11473852 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia plus a titrated IV propofol infusion (LA/PI)
Number of subjects: 100
Study 11473852 — intervention group
Group type: EXPERIMENTAL
Intervention: Minidose lidocaine-fentanyl spinal anesthesia (SAB(MLF))
Number of subjects: 100
Study 11473852 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 9761802 — intervention group
Group type: EXPERIMENTAL
Intervention: Active chiropractic manipulation
Number of subjects: 91
Study 9761802 — intervention group
Group type: COMPARATOR
Intervention: Simulated chiropractic manipulation
Number of subjects: 91